These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19841470)

  • 1. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
    Spallarossa P; Altieri P; Pronzato P; Aloi C; Ghigliotti G; Barsotti A; Brunelli C
    J Pharmacol Exp Ther; 2010 Jan; 332(1):87-96. PubMed ID: 19841470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
    Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
    Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells.
    Attia SM; Ahmad SF; Saquib Q; Harisa GI; Al-Khedhairy AA; Bakheet SA
    Mutagenesis; 2016 Mar; 31(2):137-45. PubMed ID: 26399706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panax notoginseng saponins inhibit ischemia-induced apoptosis by activating PI3K/Akt pathway in cardiomyocytes.
    Chen S; Liu J; Liu X; Fu Y; Zhang M; Lin Q; Zhu J; Mai L; Shan Z; Yu X; Yang M; Lin S
    J Ethnopharmacol; 2011 Sep; 137(1):263-70. PubMed ID: 21619920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
    Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
    Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes.
    Pentassuglia L; Timolati F; Seifriz F; Abudukadier K; Suter TM; Zuppinger C
    Exp Cell Res; 2007 May; 313(8):1588-601. PubMed ID: 17400210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
    Hasinoff BB; Schroeder PE; Patel D
    Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
    Grazette LP; Boecker W; Matsui T; Semigran M; Force TL; Hajjar RJ; Rosenzweig A
    J Am Coll Cardiol; 2004 Dec; 44(11):2231-8. PubMed ID: 15582322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death.
    Singh KK; Shukla PC; Quan A; Lovren F; Pan Y; Wolfstadt JI; Gupta M; Al-Omran M; Leong-Poi H; Teoh H; Verma S
    Biochem Biophys Res Commun; 2011 Jul; 411(2):421-6. PubMed ID: 21749857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinamide pretreatment protects cardiomyocytes against hypoxia-induced cell death by improving mitochondrial stress.
    Tong DL; Zhang DX; Xiang F; Teng M; Jiang XP; Hou JM; Zhang Q; Huang YS
    Pharmacology; 2012; 90(1-2):11-8. PubMed ID: 22699421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotective effect of zinc requires ErbB2 and Akt during hypoxia/reoxygenation.
    Viswanath K; Bodiga S; Balogun V; Zhang A; Bodiga VL
    Biometals; 2011 Feb; 24(1):171-80. PubMed ID: 20809125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways.
    Pugatsch T; Abedat S; Lotan C; Beeri R
    Breast Cancer Res; 2006; 8(4):R35. PubMed ID: 16839426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
    Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
    Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective effect of breviscapine: inhibition of apoptosis in H9c2 cardiomyocytes via the PI3K/Akt/eNOS pathway following simulated ischemia/reperfusion injury.
    Wang J; Ji SY; Liu SZ; Jing R; Lou WJ
    Pharmazie; 2015 Sep; 70(9):593-7. PubMed ID: 26492644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
    Plandé J; Platel D; Tariosse L; Robert J
    Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.
    Zhang S; Meng T; Liu J; Zhang X; Zhang J
    Medicine (Baltimore); 2015 Jan; 94(4):e445. PubMed ID: 25634181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.